Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS OTCMKTS:ALSE OTCMKTS:AOLS OTCMKTS:RNUGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/A-1.87N/AN/AALSEAlseres Pharmaceuticals$0.01$0.01$0.01▼$0.01N/AN/AN/AN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.28N/AN/ARNUGFReNeuron Group$0.00$0.00▼$0.05N/A-0.6325 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ALSEAlseres Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%RNUGFReNeuron Group0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARNUGFReNeuron GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AALSEAlseres Pharmaceuticals 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/ARNUGFReNeuron Group 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/ARNUGFReNeuron Group$640KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00N/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ARNUGFReNeuron Group-$6.52MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/ARNUGFReNeuron GroupN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AALSEAlseres PharmaceuticalsN/AAOLSAeolus PharmaceuticalsN/ARNUGFReNeuron GroupN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ALSEAlseres Pharmaceuticals8.94%AOLSAeolus Pharmaceuticals66.60%RNUGFReNeuron GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableALSEAlseres Pharmaceuticals3N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionableRNUGFReNeuron Group26N/AN/ANot OptionableRNUGF, ACUS, AOLS, and ALSE HeadlinesRecent News About These CompaniesReNeuron to Cancel London Listing; Aims to Continue as a Private CompanyAugust 30, 2024 | marketwatch.comBiotech firm Reneuron becomes latest to quit AIM as it battles for survivalAugust 30, 2024 | msn.comReNeuron set to delist after it calls time on equity fundraising effortAugust 30, 2024 | proactiveinvestors.co.ukReNeuron says funding talks ongoingAugust 2, 2024 | proactiveinvestors.co.ukReNeuron may have a future as a listed company, investors and creditors toldMay 8, 2024 | proactiveinvestors.co.ukReNeuron shares suspended as urgent cash injection neededFebruary 6, 2024 | proactiveinvestors.co.ukReNeuron to showcase drug delivery platform at Cell2023November 8, 2023 | proactiveinvestors.co.ukRugvista Group AB (RUG)October 18, 2023 | investing.comResidents on 'rough' estate with prostitutes, drugs, and needles on grass now 'dread dark nights'August 13, 2023 | gazettelive.co.ukGReNeuron appoints new scientific advisory boardApril 3, 2023 | proactiveinvestors.comReNeuron has extended cash runway as it focuses on validating its exosome platformFebruary 17, 2023 | proactiveinvestors.comReNeuron says positive iPSC data presented at conferenceDecember 8, 2022 | proactiveinvestors.comReNeuron Group says positive iPSC data presented at conferenceDecember 8, 2022 | proactiveinvestors.comReNeuron unveils jump in revenue for first-half of 2022; issues a funding updateDecember 2, 2022 | proactiveinvestors.comReNeuron Group (RENE): Re-initiation - Rebranding in Exosome Targeted Drug DeliveryNovember 3, 2022 | finance.yahoo.comReNeuron Group Names John Hawkins CFO - Quick FactsSeptember 14, 2022 | markets.businessinsider.comReneuron Group PLC's Catherine Isted on the business model, cash runway and its two legacy productsAugust 4, 2022 | proactiveinvestors.co.ukChief exec appointed at ReNeuron GroupAugust 2, 2022 | insidermedia.comIReNeuron Group PLC shares soar on impressive data from latest breakthroughOctober 11, 2021 | proactiveinvestors.co.ukReNeuron Group plc - Posting of AR and Accounts and Notice of AGMAugust 16, 2021 | proactiveinvestors.co.ukRNUGF, ACUS, AOLS, and ALSE Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.Alseres Pharmaceuticals OTCMKTS:ALSE$0.0050 0.00 (0.00%) As of 10/18/2024Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.ReNeuron Group OTCMKTS:RNUGFReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
